Schering-Plough weathers foreign exchange impact; posts income growth - update
This article was originally published in Scrip
Schering-Plough's sales were hit substantially by unfavourable foreign exchange rates during the second quarter. The returning strength of the US dollar dampened its total net sales, but tighter cost controls were a boon for its net profits
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.